Concurrent inactivation of PTEN and RB1 have previously been described as a mechanism for loss of BRAF/MEK dependence in BRAFV600E mutated melanomas [25] and the cell cycle progression pathway including RB1 have been associated to BRAF inhibitors resistance [26–28]. Here, BRAF is linked to melanoma.